Pharmacotherapy of Neuroleptic Malignant Syndrome
1991; Slack Incorporated (United States); Volume: 21; Issue: 3 Linguagem: Inglês
10.3928/0048-5713-19910301-08
ISSN1938-2456
AutoresP. Sakkas, John M. Davis, Hua Jin, Z Wang,
Tópico(s)Takotsubo Cardiomyopathy and Associated Phenomena
ResumoNeuroleptic Malignant SyndromePharmacotherapy of Neuroleptic Malignant Syndrome Paul Sakkas, MD, , , MD John M Davis, MD, , , MD Jin Hua, MD, , and , MD Z Wang, MS, , MS Paul Sakkas, MD , John M Davis, MD , Jin Hua, MD , and Z Wang, MS Published Online:March 01, 1991https://doi.org/10.3928/0048-5713-19910301-08PDFView Full Text ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInRedditEmail SectionsMore1. Addonizio G1 Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive patients. AmJ Psychiatn 19HlV. 143:1587-1590. Google Scholar2. Susman VL1 Addonizio G. Recurrence of neuroleptic malignant syndrome. Proceedings of the Annual Meeting of the APA. 1985;23:159-160. Google Scholar3. Kuno S, Komme O, Mizuta F.. Yamazaki S, Nishitani H. Neuroleptic malignant syndrome associated with withdrawal of antiparkinsonian drugs. Movement Disorders. 1990;5(suppl I): 171. Google Scholar4. Truong DD, Sczesni B. Fahn S, el al. Das neuroleptische maligne syndrom (dopammabhangige maligne hyperthermic). Nervenarzt. 1988; 59: 103-109. Google Scholar5. Mueller PS, VesterJE, Fermaglieli J. Neuroleptic malignant syndrome: successful treatment with bromocriptine. JAMA. 1983;249:386-388. Google Scholar6. Granato JE, Stern BJ. Ringel A, et al. Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine. Ann Nettivi. 1983: 14:8990. Google Scholar7. Khan A, JaffeJH, Nelson VVH, Morrison B. Resolution of neuroleptic malignant syndrome with dantrolene sodium: case repon. J Clin Psychiatry 1985; 46:244-246. Google Scholar8. Dhibjalbui S, Hesselbrock R, Mouradian MM. Means ED. Bromocriptine treatment of neuroleptic malignarti syndrome. J Clin Psychiatry 1987: 48:69-73. Google Scholar9. Amdurski S. Radwan M. Levi A, Eli/ur A. A therapeutic trial of amantadine in haloperidol-induced neuroleptic malignant syndrome. Current Therapeutic Research. 1983: 33:225-229. Google Scholar10 Bismuth C, de Rohan-Chabol P. Gonion M. Raphael JC. Dantrolene - a new therapeutic approach to the neuroleptic malignant syndrome. Acta Neurol Stand. 1981: 70(slOG):193-l98. Google Scholar11. Hamburg P, Weilburg JB, Cassetti NH. Cohen L, Brown S. Relapse of neuroleptic malignant syndrome with early discontinuation ut amantadine therapy. Compr Psychiatry 1986; 27:272-275. Google Scholar12. Lazarus A. Neuroleptic malignant syndrome and amantadine withdrawal. AmJ Psychiatn 1985: 142:894. Google Scholar13 Harsh HH. Neuroleptic malignant syndrome: physiological and laboratory findings in a series of nine cases. J Clin Psychiatry 1987: 48:328-333. Google Scholar14 Woo J, Teoh R, Vallance-Owen J. Neuroleptic malignan I syndrome successfully treated with amantadine. Postgrad Med J. 1 986; 62:809-8 10. Google Scholar15. Price DK. Turnbull CJ. Gregory RP. Stevens DC. Neuroleptic malignant syndrome in a case of postpartum psychosis. Br J Psychiatry. 1989: 155:849-852. Google Scholar16. Renfordt E, Wardin B. Elektrokrampi und dantrolen behandlung einer febrilen katatonie. Nervenarzt. 1985; 56: 15.3- 156. Google Scholar17. Rosenberg MR. Green M. Neuroleptic malignant syndrome. Arch Interri 1989: 149:1927-1931. Google Scholar18. Rosenbush P. Stewart T. A prospective analysis of 24 episodes of neuroleptic malignan! syndrome. Am J Psychiatry 1989; 146(6) Google Scholar19. Knpenen H. Repo E, Lapola LT. Neuroleptic malignant syndrome. Biol Psych. 1988;24:943-944. Google Scholar20. tac S, Men iam A, Kim T-S, Lcibling M. Dickson DW. Moore CiRW. degeneration in neuroleptic malignant syndrome. J Neurol Neurosurg Psychiatry 1 989; 52:387-391. Google Scholar21. Lcvcuson JL. Neuroleptic malignant drome. Am f Psychiatry. 1985: 142:113711 45. Google Scholar22. Shak-v A, Hermesh H, Munit/ H. The role of external heat load in NMS. AmJ Psychiatry 1988; 145:1 10-111. Google Scholar23. Chayasirisobhon S, Cuius P. Veeramasuneni RR. Occurrence of NMS in a narcoleptic patient. Hosp Community Psychiatry. 1983; 34:548-550. Google Scholar24. Rojman M, Apter E, Lehav S. dine- in NMS. Harefuah J Israel. 1981; 100: 320-333. Google Scholar25. McGarron MM. Boettgher ML. Peck J]. A case of neuroleptic malignant syndrome successfully treated with amantadine. J Clin Psychiatn 1982: 43:381-382. Google Scholar26. Straker M. Neuroleptic malignant syndrome: fatalities associated with neuroleptic use and schizophrenia. J Univ Ottawa, 1986; 1 1:28-30. Google Scholar27. Eles CR, Songer [E, Dipette DJ. Neuroleptic malignant syndrome complicated by disseminated intravascular agulation. Arch Intern Med. 1984; 144:1296-1297. Google Scholar28. Hashimoto F, Sherman CB, Jeflery Neuroleptic malignant syndrome and dopaminergic blockade. Arch Intent Med. 1984: 144:629-630. Google Scholar29. Manin ML, Lucid E], Walker RW. Neuroleptic malignant syndrome. Ann Emerg Med. 1985: 14:354-358. Google Scholar30. Harris M. Nora L. Tanner CM. NMS responsive to carbidopa/levodopa: support for a dopaminergic pathogenesis. Clin Neuiopharmarol. 1987; 10:186-189. Google Scholar31. Devanand DP, Sackeint HA. Fink AD. Case report: modified ECT using succinylcholine after remission of neuroleptic malignant syndrome. Convulsive Therapy 1987; 3:284-290. Google Scholar32. Pearlman C, Levine J. Neuroleptic malignant syndrome. J Clinical Pharmacol. 1980; 6:257-272. Google Scholar33. Bond WS. Detection and management of the NMS. Clin Pharm. 1984: 3:302-307. Google Scholar34. Nisijima K. Ishiguro T. Neuroleptic malignant syndrome: A study of CSF monoamine. Biol Psychiatn 1990: 27:280288. Google Scholar35. Klein SK, Levinsohn MW. Blum JL. ,Accidental chlorpromazine ingestion as a cause of NMS in children. J Pediatr: 1985: 1 07:970-973. Google Scholar36. Goulon M. de Rohan-Chabol P. Elkharrat D. Ghajados P, Bismuti) O. Const) F. Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases. Neurology 1983;33:516-518. Google Scholar37. Konikoff F. Kuril/ky A, Jeruslialmi Y Theodor E. Neuroleptic malignant syndrome induced by a single injection of haloperidol. Br Med J 1984; 289:12281229. Google Scholar38. Dense hi C, Oepen C Hermie L. Kindt H. Neuroleptic malignant syndrome: observations on altered consciousness. Pharmacopsychiatry 1987; 20:168-170. Google Scholar39. Lew T-V Tollefson C. Chlorpronia/incinduced neuroleptic malignant syndrome and its response to diazepam. Biol Psychiatry 1 98.3; 18: J 44 J -1 446. Google Scholar40. Scarlett JD, Zimmerman R. Berkovic: SE. Neuroleptic malignant syndrome. Ausi N Zf Med. 1983; 13:70-73. Google Scholar41. Yasukawa M. Hatakeyama V Yasukawa K, Chiba S1 Suzuki T. A case of neuroleptic malignant syndrome with myoglobinuria. Afono. i983; 33:876382. Google Scholar Previous article Next article FiguresReferencesRelatedDetails Request Permissions InformationCopyright 2013, SLACK IncorporatedPDF download
Referência(s)